L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents
Metrics: PDF 2476 views | HTML 2689 views | ?
Laura Conti1,*, Stefania Lanzardo1,*, Roberto Ruiu1, Marta Cadenazzi1, Federica Cavallo1, Silvio Aime1, Simonetta Geninatti Crich1
1Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy
*These authors have contributed equally to this work
Stefania Lanzardo, email: [email protected]
Simonetta Geninatti Crich, email: [email protected]
Keywords: ferritin, cancer stem cells, theranostic agents, magnetic resonance imaging, mammary tumors
Received: February 23, 2016 Accepted: July 18, 2016 Published: July 29, 2016
A growing body of evidence suggests that cancer stem cells (CSC) have the unique biological properties necessary for tumor maintenance and spreading, and function as a reservoir for the relapse and metastatic evolution of the disease by virtue of their resistance to radio- and chemo-therapies. Thus, the efficacy of a therapeutic approach relies on its ability to effectively target and deplete CSC. In this study, we show that CSC-enriched tumorspheres from breast cancer cell lines display an increased L-Ferritin uptake capability compared to their monolayer counterparts as a consequence of the upregulation of the L-Ferritin receptor SCARA5. L-Ferritin internalization was exploited for the simultaneous delivery of Curcumin, a natural therapeutic molecule endowed with antineoplastic action, and the MRI contrast agent Gd-HPDO3A, both entrapped in the L-Ferritin cavity. This theranostic system was able to impair viability and self-renewal of tumorspheres in vitro and to induce the regression of established tumors in mice. In conclusion, here we show that Curcumin-loaded L-Ferritin has a strong therapeutic potential due to the specific targeting of CSC and the improved Curcumin bioavailability, opening up the possibility of its use in a clinical setting.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.